BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 17438148)

  • 1. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Platelet Glycoprotein Receptor Blockade in Aged and Comorbid Mice With Acute Experimental Stroke.
    Kraft P; Schuhmann MK; Fluri F; Lorenz K; Zernecke A; Stoll G; Nieswandt B; Kleinschnitz C
    Stroke; 2015 Dec; 46(12):3502-6. PubMed ID: 26486866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-glycoprotein Ib causes platelet aggregation: different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer.
    O'Brien JR; Etherington MD
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):453-61. PubMed ID: 9818994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
    Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
    Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
    Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
    Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification of human platelet specific functional antibody and its fragments].
    Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb.
    Massberg S; Schürzinger K; Lorenz M; Konrad I; Schulz C; Plesnila N; Kennerknecht E; Rudelius M; Sauer S; Braun S; Kremmer E; Emambokus NR; Frampton J; Gawaz M
    Circulation; 2005 Aug; 112(8):1180-8. PubMed ID: 16103235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
    Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
    Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report.
    De Meyer SF; Schwarz T; Deckmyn H; Denis CV; Nieswandt B; Stoll G; Vanhoorelbeke K; Kleinschnitz C
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1949-51. PubMed ID: 20616311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glycoprotein Ib or von Willebrand factor.
    Cauwenberghs N; Schlammadinger A; Vauterin S; Cooper S; Descheemaeker G; Tornai I; Deckmyn H
    Thromb Haemost; 2001 Apr; 85(4):679-85. PubMed ID: 11341505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats.
    Li H; Lockyer S; Concepcion A; Gong X; Takizawa H; Guertin M; Matsumoto Y; Kambayashi J; Tandon NN; Liu Y
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1199-205. PubMed ID: 17322098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures.
    Pasha R; Benavides M; Kottke-Marchant K; Harasaki H
    Lab Invest; 1995 Sep; 73(3):403-8. PubMed ID: 7564273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-Reperfusion Injury.
    Pachel C; Mathes D; Arias-Loza AP; Heitzmann W; Nordbeck P; Deppermann C; Lorenz V; Hofmann U; Nieswandt B; Frantz S
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):629-35. PubMed ID: 26916731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking of platelet glycoprotein receptor Ib reduces "thrombo-inflammation" in mice with acute ischemic stroke.
    Schuhmann MK; Guthmann J; Stoll G; Nieswandt B; Kraft P; Kleinschnitz C
    J Neuroinflammation; 2017 Jan; 14(1):18. PubMed ID: 28109273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
    Choudhri TF; Hoh BL; Zerwes HG; Prestigiacomo CJ; Kim SC; Connolly ES; Kottirsch G; Pinsky DJ
    J Clin Invest; 1998 Oct; 102(7):1301-10. PubMed ID: 9769322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.